Madrigal Pharmaceuticals, Inc. reported significant financial results for the third quarter of 2025, driven primarily by the commercial launch of its product, Rezdiffra, which is approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company generated $287.3 million in product revenue for the three months ended September 30, 2025, a substantial increase of 362% compared to $62.2 million in the same period last year. For the nine months ended September 30, 2025, total product revenue reached $637.3 million, up 730% from $76.8 million in the prior year. Despite this revenue growth, Madrigal reported a net loss of $114.2 million for the quarter, slightly higher than the $107.0 million loss recorded in the third quarter of 2024.
Operating expenses for the third quarter of 2025 totaled $401.2 million, a 125% increase from $178.5 million in the same quarter of 2024. This rise was attributed to increased costs associated with sales and marketing efforts for Rezdiffra, as well as heightened research and development expenditures, which amounted to $174.0 million, up 153% from the previous year. The company’s selling, general, and administrative expenses also surged to $209.1 million, reflecting a 94% increase as Madrigal expanded its commercial operations and workforce to support the product launch.
In terms of operational developments, Madrigal successfully launched Rezdiffra in Germany in September 2025, following its approval by the European Commission in August 2025. The company is also conducting ongoing clinical trials to evaluate Rezdiffra's efficacy in a broader patient population, including those with compensated MASH cirrhosis. As of September 30, 2025, Madrigal reported total assets of $1.36 billion, up from $1.04 billion at the end of 2024, with cash and cash equivalents increasing to $295.7 million from $100.0 million.
Madrigal's strategic initiatives included entering into a senior secured credit facility in July 2025, providing up to $500 million to support its operations and product development. The company repaid its previous Hercules Loan Facility, which amounted to $121.7 million, and incurred a loss of $2.8 million on extinguishment of that debt. Looking ahead, Madrigal anticipates continued investment in commercialization efforts and clinical trials, with expectations of incurring losses until it can generate sufficient revenue from Rezdiffra and other potential products. The company believes its current cash reserves will be adequate to fund operations for at least the next year, although it may seek additional capital to support its long-term growth objectives.
About MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing therapies for metabolic liver diseases, primarily nonalcoholic steatohepatitis (MASH). Its flagship product, Rezdiffra (resmetirom), is a liver-directed oral therapy targeting fibrosis and inflammation. The company aims to address high unmet medical needs, expand indications, and obtain regulatory approvals globally, leveraging proprietary technology and strategic collaborations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.